Metformina Dinerfene Laboratórios Azevedos - Indústria Farmacêutica

Metformin Hydrochloride, the active ingredient in Metformina Dinerfene, is a biguanide presented as an oral tablet for oral use. It lowers blood glucose levels and is indicated for the management of type 2 diabetes mellitus and related glucose‑handling disorders. It improves peripheral insulin sensitivity and reduces hepatic glucose output, helping achieve glycemic control.

GNH USA supplies Metformina Dinerfene as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Metformina Dinerfene (metformin hydrochloride) is used to improve glycemic control in several glucose‑regulation disorders.

- Type 2 diabetes mellitus: reduces fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes. - Gestational diabetes mellitus: assists in controlling maternal blood glucose when diet alone is insufficient.

Metformina Dinerfene may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Vomiting: occasional emesis.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycemia: especially when combined with insulin or sulfonylureas. - Vitamin B12 deficiency: anemia and neuropathy with long‑term use.

Before initiating Metformina Dinerfene, several safety considerations should be reviewed. - Renal function assessment: evaluate eGFR and avoid use if severe renal impairment. - Hepatic function monitoring: check liver enzymes periodically. - Contraindication in severe renal disease: do not prescribe if eGFR <30 mL/min/1.73 m². - Use with caution in elderly: increased risk of lactic acidosis. - Monitor vitamin B12 levels: long‑term therapy may cause deficiency. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Metformina Dinerfene can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol excess: enhances risk of lactic acidosis. - Renal‑impairing drugs (e.g., NSAIDs, ACE inhibitors): may reduce metformin clearance.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Sulfonylureas or insulin: increase risk of hypoglycemia. - Diuretics (thiazides): may affect glucose control. - Warfarin: may require INR monitoring. - Thyroid hormones: may alter glycemic response.